AMLX241220C11000
- 0.05
- 0.000.00%
Amylyx Pharmaceuticals Newsroom
Express News | Amylyx Pharmaceuticals Shares up 1.7% on Late-Stage Trial Update for Low-Blood Sugar Drug
Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
Express News | Amylyx Pharmaceuticals Inc - First Participant in Lucidity Trial Expected in Q1 2025
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Express News | Amylyx Pharmaceuticals Announces Pivotal Phase 3 Lucidity Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
Baird Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Raises Target Price to $11
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Amylyx Pharmaceuticals Raised to Outperform From Neutral by Baird
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Cautious Hold on Amylyx Pharmaceuticals Amid Uncertainty in Pipeline Progress
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript Summary
Amylyx Pharma Analyst Ratings
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $12
Express News | Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $12 From $8
Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call
Amylyx Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Amylyx Pharmaceuticals Inc: Cash Runway Expected Into 2026
Amylyx Pharmaceuticals | 8-K: Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results